CNB-001, a novel pyrazole derivative mitigates motor impairments associated with neurodegeneration via suppression of neuroinflammatory and apoptotic response in experimental Parkinson's disease mice

Chemico-Biological Interactions

Volumn 220, Issue , 2014, Pages 149-157

  Jayaraj, Richard L ^a   Elangovan, Namasivayam ^a   Dhanalakshmi, Chinnasamy ^b   Manivasagam, Thamilarasan ^b   Essa, Musthafa Mohamed ^c  

^a PERIYAR UNIVERSITY   (India)

^b ANNAMALAI UNIVERSITY   (India)

^c SULTAN QABOOS UNIVERSITY   (Oman)

Author keywords

Apoptosis; CNB 001; Inflammation; MPTP; Parkinson's disease

Indexed keywords

4,4' [(1 PHENYL 1H PYRAZOLE 3,5 DIYL)DIETHENE 2,1 DIYL]BIS(2 METHOXYPHENOL); BIOLOGICAL MARKER; CASPASE 3; CITRULLINE; CYCLOOXYGENASE 2; CYTOCHROME C; DOPAMINE; DOPAMINE TRANSPORTER; GLIAL FIBRILLARY ACIDIC PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; NITRITE; PROTEIN BAX; PROTEIN BCL 2; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; CURCUMIN; PYRAZOLE DERIVATIVE;

ADULT; AKINESIA; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; ASTROCYTE; CATALEPSY; CELL ACTIVATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DOPAMINE BLOOD LEVEL; DOPAMINERGIC NERVE CELL; DRUG DOSE COMPARISON; DRUG STRUCTURE; EXPERIMENTAL BEHAVIORAL TEST; EXPERIMENTAL PARKINSONISM; MALE; MOTOR DYSFUNCTION; MOUSE; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; OPTIMAL DRUG DOSE; PROTEIN EXPRESSION; STRIATONIGRAL DEGENERATION; STRUCTURE ANALYSIS; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; CHEMICAL STRUCTURE; DISEASE MODEL; DRUG EFFECTS; IMMUNOHISTOCHEMISTRY; MOTOR ACTIVITY; PARKINSON DISEASE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; APOPTOSIS; CURCUMIN; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED C57BL; MOLECULAR STRUCTURE; MOTOR ACTIVITY; PARKINSON DISEASE; PYRAZOLES;

EID: 84904568487     PISSN: 00092797     EISSN: 18727786     Source Type: Journal    
DOI: 10.1016/j.cbi.2014.06.022     Document Type: Article

References (43)

1. A.L. Bartels, and K.L. Leenders Neuroinflammation in the patho-physiology of Parkinson's disease: evidence from animal models to human in vivo studies with [11C]-PK11195 PET Mov. Disord. 22 2007 1852 1856 (Pubitemid 350134195)
2. R.S. Burns, D.D. Chiueh, S.P. Markey, M.H. Eber, D.M. Jacobowitz, and I.J. Kopin A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6- tetrahydropyridine Proc. Natl. Acad. Sci. U.S.A. 80 1980 4546 4550 (Pubitemid 13077876)
3. S. Przedborski, V. Jackson-Lewis, R. Yokoyama, T. Shibata, V.L. Dawson, and T.M. Dawson Role of neuronal nitric oxide in 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminer-gic neurotoxicity Proc. Natl. Acad. Sci. U.S.A. 93 1993 4565 4571
4. R.P. Ojha, M. Rastogi, B.P. Devi, A. Agrawal, and G.P. Dubey Neuroprotective effect of curcuminoids against inflammation-mediated dopaminergic neurodegeneration in the MPTP model of Parkinson's disease J. Neuroimmune Pharmacol. 7 2012 609 618
5. F. Ros-Bernal, S. Hunot, M.T. Herrero, S. Parnadeau, J.C. Corvol, L. Lu, D. Alvarez-Fischer, M.A. Carrillo-de Sauvage, F. Saurini, C. Coussieu, K. Kinugawa, A. Prigent, G. Höglinger, M. Hamon, F. Tronche, E.C. Hirsch, and S. Vyas Microglial glucocorticoid receptors play a pivotal role in regulating dopaminergic neurodegeneration in parkinsonism Proc. Natl. Acad. Sci. U.S.A. 108 2011 6632 6637
6. A. Anandhan, M.M. Essa, and T. Manivasagam Therapeutic attenuation of neuroinflammation and apoptosis by black tea theaflavin in chronic MPTP/probenecid model of Parkinson's disease Neurotox. Res. 23 2013 166 173
7. G.M. Cole, B. Teter, and S.A. Frautschy Neuroprotective effects of curcumin Adv. Exp. Med. Biol. 595 2007 197 212
8. B.B. Aggarwal, and K.B. Harikumar Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases Int. J. Biochem. Cell Biol. 41 2009 40 59
9. P. Anand, A.B. Kunnumakkara, R.A. Newman, and B.B. Aggarwal Bioavailability of curcumin: problems and promises Mol. Pharm. 4 2007 807 818
10. Y. Liu, R. Dargusch, P. Maher, and D. Schubert A broadly neuroprotective derivative of curcumin J. Neurochem. 105 2008 1336 1345 (Pubitemid 351590797)
11. R.L. Jayaraj, K. Tamilselvam, T. Manivasagam, and N. Elangovan Neuroprotective effect of CNB-001, a novel pyrazole derivative of curcumin on biochemical and apoptotic markers against rotenone-induced SK-N-SH cellular model of Parkinson's disease J. Mol. Neurosci. 51 2013 863 870
12. A. Anandhan, U. Janakiraman, and T. Manivasagam Theaflavin ameliorates behavioral deficits, biochemical indices and monoamine transporters expression against subacute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mouse model of Parkinson's disease Neuroscience 218 2012 257 267
13. O. Narumoto, Y. Matsuo, M. Sakaguchi, S. Shoji, N. Yamashita, D. Schubert, K. Abe, K. Horiguchi, T. Nagase, and N. Yamashita Suppressive effects of a pyrazole derivative of curcumin on airway inflammation and remodeling Exp. Mol. Pathol. 93 2012 18 25
14. K.R. Rekha, G.P. Selvakumar, S. Sethupathy, K. Santha, and R.I. Sivakamasundari Geraniol ameliorates the motor behavior and neurotrophic factors inadequacy in MPTP-induced mice model of Parkinson's disease J. Mol. Neurosci. 2013 10.1007/s12031-013-0074-9
15. S. Rajasankar, T. Manivasagam, and S. Surendran Ashwagandha leaf extract: a potential agent in treating oxidative damage and physiological abnormalities seen in a mouse model of Parkinson's disease Neurosci. Lett. 454 2009 11 15
16. D. Muralikrishnan, and K.P. Mohanakumar Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyr-idine-induced neurotoxicity in mice FASEB J. 12 1998 905 912 (Pubitemid 28294680)
17. K.B.J. Franklin, and G. Paxinos The Mouse Brain in Stereotaxic Coordinates 2007 Academic Press London
18. K. Raddassi, B. Berthon, J.F. Petit, and G. Lemaire Role of calcium in the activation of mouse peritoneal macrophages: induction of NO synthase by calcium ionophores and thapsigargin Cell. Immunol. 53 1994 443 455 (Pubitemid 24078620)
19. T.R.C. Boyde, and M. Rahmatullah Optimization of conditions for the colorimetric determination of citrulline, using diacetyl monoxime Anal. Biochem. J. 107 1980 424 431 (Pubitemid 11220248)
20. O.H. Lowry, N.J. Rosebrough, A.L. Farr, and R.J. Randall Protein measurement with the Folin phenol reagent J. Biol. Chem. 193 1951 265 275
21. S.M. Fleming, J. Salcedo, P.O. Fernagut, E. Rockenstein, E. Masliah, M.S. Levine, and M.F. Chesselet Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein J. Neurosci. 24 2004 9434 9440 (Pubitemid 39426179)
22. K.Y. Tseng, L. Kargieman, S. Gacio, L.A. Riquelme, and M.G. Murer Consequences of partial and severe dopaminergic lesion on basal ganglia oscillatory activity and akinesia Eur. J. Neurosci. 22 2005 2579 2586 (Pubitemid 41759000)
23. C. Lu, J. Zhang, X. Shi, S. Miao, L. Bi, S. Zhang, Q. Yang, X. Zhou, M. Zhang, Y. Xie, Q. Miao, and S. Wang Neuroprotective effects of tetramethylpyrazine against dopaminergic neuron injury in a rat model of Parkinson's disease induced by MPTP Int. J. Biol. Sci. 10 2014 350 357
24. W. He, W. Chen, Y. Zhou, Y. Tian, and F. Liao Xanthotoxol exerts neuroprotective effects via suppression of the inflammatory response in a rat model of focal cerebral ischemia Cell. Mol. Neurobiol. 33 2013 715 722
25. P. Thakur, and B. Nehru Anti-inflammatory properties rather than anti-oxidant capability is the major mechanism of neuroprotection by sodium salicylate in a chronic rotenone model of Parkinson's disease Neuroscience 231 2013 420 431
26. G.C. Brown, and A. Bal-Price Inflammatory neurodegeneration mediated by nitric oxide, glutamate, and mitochondria Mol. Neurobiol. 27 2003 325 355 (Pubitemid 38156291)
27. A. Bal-Price, and G.C. Brown Inflammatory neurodegeneration mediated by nitric oxide from activated glia-inhibiting neuronal respiration, causing glutamate release and excitotoxicity J. Neurosci. 21 2001 6480 6491 (Pubitemid 32781092)
28. Y. Du, Z. Ma, S. Lin, R.C. Dodel, F. Gao, K.R. Bales, L.C. Triarhou, E. Chernet, K.W. Perry, D.L. Nelson, S. Luecke, L.A. Phebus, F.P. Bymaster, and S.M. Paul Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease Proc. Natl. Acad. Sci. U.S.A. 98 2001 14669 14674 (Pubitemid 33121449)
29. M.C. Pott-Godoy, C.C. Ferrari, and F.J. Pitossi Nigral neurodegeneration triggered by striatal AdIL-1 administration can be exacerbated by systemic IL-1 expression J. Neuroimmunol. 222 2010 29 39
30. J. Guadagno, X. Xu, M. Karajgikar, A. Brown, and S.P. Cregan Microglia-derived TNFα induces apoptosis in neural precursor cells via transcriptional activation of the Bcl-2 family member Puma Cell Death Dis. 4 2013 e538
31. D.C. Wu, V. Jackson-Lewis, M. Vila, K. Tieu, P. Teismann, C. Vadseth, D.K. Choi, H. Ischiropoulos, and S. Przedborski Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine mouse model of Parkinson disease J. Neurosci. 22 2002 1763 1771 (Pubitemid 35386294)
32. L.S. Forno, L.E. DeLanney, I. Irwin, D. Di Monte, and J.W. Langston Astrocytes and Parkinson's disease Prog. Brain Res. 94 1992 429 436 (Pubitemid 23026667)
33. A.B. Reksidler, M.M. Lima, S.M. Zanata, H.B. Machado, C. da Cunha, R. Andreatini, S. Tufik, and M.A. Vital The COX-2 inhibitor parecoxib produces neuroprotective effects in MPTP-lesioned rats Eur. J. Pharmacol. 560 2007 163 175 (Pubitemid 46341312)
34. D. Litteljohn, E. Mangano, M. Clarke, J. Bobyn, K. Moloney, and S. Hayley Inflammatory mechanisms of neurodegeneration in toxin-based models of Parkinson's disease Parkinsons Dis. 2011 2011 71351
35. T.G. Hastings Enzymatic oxidation of dopamine: the role of prostaglandin H synthase J. Neurochem. 64 1995 919 924
36. Z.H. Feng, T.G. Wang, D.D. Li, P. Fung, B.C. Wilson, B. Liu, S.F. Ali, R. Langenbach, and J.S. Hong Cyclooxygenase-2-deficient mice are resistant to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced damage of dopaminergic neurons in the substantia nigra Neurosci. Lett. 329 2002 354 358 (Pubitemid 35245358)
37. T. Furuya, H. Hayakawa, M. Yamada, K. Yoshimi, S. Hisahara, M. Miura, Y. Mizuno, and H. Mochizuki Caspase-11 mediates inflammatory dopaminergic cell death in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease J. Neurosci. 24 2004 1865 1872 (Pubitemid 38292797)
38. M.A. Burguillos, T. Deierborg, E. Kavanagh, A. Persson, N. Hajji, A. Garcia-Quintanilla, J. Cano, P. Brundin, E. Englund, J.L. Venero, and B. Joseph Caspase signalling controls microglia activation and neurotoxicity Nature 472 2011 319 324
39. R.T. Mallet, J. Sun, E.M. Knott, A.B. Sharma, and A.H. Olivencia-Yurvati Metabolic cardioprotection by pyruvate: recent progress Exp. Biol. Med. (Maywood) 230 2005 435 443 (Pubitemid 40923420)
40. M. D'Amelio, M. Sheng, and F. Cecconi Caspase-3 in the central nervous system: beyond apoptosis Trends Neurosci. 35 2012 700 709
41. J.M. Adams, and S. Cory The Bcl-2 protein family: arbiters of cell survival Science 281 1998 1322 1326 (Pubitemid 28406819)
42. R. Kurosaki, Y. Muramatsu, H. Watanabe, M. Michimata, M. Matsubara, Y. Imai, and T. Araki Role of dopamine transporter against MPTP (1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine) neurotoxicity in mice Metab. Brain Dis. 18 2003 139 146 (Pubitemid 36718126)
43. G. Kavitha, J. Nataraj, M.M. Essa, M.A. Menon, and T. Maivasagam Mangiferin attenuates MPTP induced dopaminergic neurodegeneration and improves motor impairment, redox balance and Bcl-2/Bax expression in experimental Parkinson's disease mice Chem. Biol. Interact. 206 2013 239 247